Will Moderna break 86.7 resistance?Will MRNA break 86.7 based on it's Covid-19 vaccine work?
NOTE: Although not a recommendation, if you like my work, please donate a few coins. Thanks.
PHARMA
Major Wave Higher? Or down we go 🎩We maybe have finished movement inside this monthly downward channel, which looks like a corrective channel for previous bullish impulse. Chances are we will go north from here. But if price will brake this channel downwards it may as well become ugly, and there is no support levels, I guess?
Anyway, now GILD highly tightened to SNP and thus electional uncertainty.
VLA [LONG] Covid CashNews looks positive for this company to produce a new vaccine for the UK, if proved safe would go global. A sound investment opportunity.
Can see it rising today.
AstrazenecaSo they had a death on the vaccine research and look to be forming a head and shoulder pattern which is typical of a reversal in price, how come the news always comes so in time? the markets are so fascinating.
Growth potentialThe pharmaceutical sector is one of the most interesting ones in such a troubled period.
I see some growth potential for $ACAD in the short term. It is showing a positive trend that is already consolidated and heading for a possible TP of around 44-45$
I see this level as an important resistance since it has been tested repeatedly in the past.
***As usual, not a trading advice, merely my view for informational and educational purposes only***
PHARM ; Possible bullish pullbackIf it stays above the support today, a buy signal will occur for Monday.
$CLVS Triangular TIPZ close to the X'zCLOVIS maker of FDA approved Rubraca® which is a treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy. www.rubraca.com
Sitting at a pretty interesting area right now, sure it will get some more movement soon as we are at a crucial area. Plus last time I reviewed the sec docs it seemed to me like they were lowering net-losses & striving towards profits.
DYI: www.sec.gov
BIOCON:NSE - BULLISH FOR LONG -WITH CUP & HANDLE PATTERNWeekly chart shows very bullish from march this Year, Entry @ Rs 256 march 2020, I believe BIOCON will cross 800 by next March-April-2021.
Divis Laboratories Sell for TGT 2850RSI Divergence on Daily Chart
Window / Gap from Rs.2784 to Rs.3063
Considering Stock has closed around Rs.3050 for 2 consecutive day, any fall from hereon would cause the stock the to fall to Rs.2784 levels.
Suggestion: Sell a Call at CMP 3050 / 3000 with a SL Rs.3120.
RLFTF - Penny Stock Heating UpAnticipating some positive news from RLFTF's and further FDA approval for it's Aviptadil.
ABCDE Triagle wave approaching completion, confirmed by Williams Alligator, and Fib Retracement
A bounced off 0.382 level
C bounced off 0.5 level
Look for E confirmation off 0.618 level
Should price exit the triangle formation, setting target @ $1.2
Glenmark at SupportGlenmark at Crucial Support of 459, if breaks, then can test 418, if consolidates at 459-465 then can give move up to 540 by 20th September 2020. Wait and watch if 459-456 levels are respected.
#SUVENPHAR #BANKNIFTY #NIFTY #TRADING #COVID19 #SUVEN #PHARMA#SUVENPHAR #SUVEN
Suven Pharmaceuticals Ltd.
CMP: 676.90
Target: 708 / 750
SL: 644
Pharma looks fugly on a relative basisBreaking down through support, this is what kept me out of trading PFE to the long-side even though it looked bullish. With the elections coming up and democrats leading the polls, I'd stay away from pharma and insurers. Lean towards medical devices if you need healthcare exposure.
Sun pharmaHello!! Sun pharma is a great stock now. this stock is in an indecisive position wait for the confirmation as if it breaks the support of 522 then lower levels can be seen but if it sustains over it then around 553 can be seen. #MY_VIEW #LEARNER
BIOSEARCH: Potential H&S despite good fundamentalsOn July 10, after issuing a warning that the firm would expect higher than usual profits, BIOS jumped >20% that friday. Then, once its quarterly earnings were released, it was clear the company had not tricked us: + 25.8% REVENUES OF 14.3 MILLION IN THE FIRST SEMESTER, +44.2% to 5.5 million euros in Plant extracts business line, probiotics business registered a growth of 47.4%, standing at 3.2 million euros, driven mainly by the Women’s Health segment. Net profit was up +501,7% in the first semester of 2020. EBITDA of €1,96 million (+92,8% Semester over Semester).
However, technical analysis suggests to short the company until 1.04 or even 0.95 level (and some other analysts from FX Street say 0.87). As it is usual in summer, the company is experiencing low volume levels so if volume starts increasing, BIOS' share price may go up easily as Reig Jofre or ROVI did. So, long-term trend is bullish up until 2018 maximums of 1.95-2€. August is bearish.
relatively high PER: (57*1.13)/1.04 = 62
Not higher than RJFE's PER = 77
ROVI's PER = 95
And lower than:
FAES FARMA PER = 21.53 (very undervalued in my opinion)
PHARMA MAR PER = 14 (unstable company, needs more history to determine its viability. it could certainly be a good investment due to its low PER, but remember first semester 2019 it experienced losses instead of profits)
These PERs here were calculated based on net profit from first semester 2020 only.
Is this Hikma's cue for a break out?Will Hikma break out after a 5 year H&S pattern,
now that it's making progress in the Covid-19 vaccine business?
